Seroprevalence of SARS-CoV-2 Antibodies among vaccinated and nonvaccinated adults in the West Bank: Results of a repeated cross-sectional study

Faisal Awartani, Arab American University of Palestine (AAUP), Ramallah, Palestine, faisal.awartani@gmail.com

Faisal Awartani department of health sciences, AAUP, Ramallah, Palestine Nouar Qutob, department of health sciences, AAUP, Ramallah, Palestine Mohammad Asia, department of health sciences, AAUP, Ramallah, Palestine Waleed Theib , department of health sciences, AAUP, Ramallah, Palestine

ABSTRACT

Background

Seroprevalence studies provide an accurate measure of SARS-CoV-2 spread at a population level and the number of undiagnosed individuals. Repeated cross-sectional sero-studies are encouraged to monitor the spread of the virus. The aim of this study is to assess the seroprevalence rate among a random sample of Palestinians residing in the West Bank region of Palestine.

Methods

This second round cross-sectional study involved 1451 participants. serologic testing of a random sample of vaccinated and non-vaccinated adults, 18 years and older residing in 11 governorates of the West Bank region of Palestine. Antibodies/Blood samples were taken using Elecsys Anti-SARS-CoV-2 assay by using the Cobas Analyzer cobas e 411 (Roche) for detection of antibody seropositivity against COVID-19.

Serological tests for 910 adequate serum samples were done using immunoassays for detection of antibodies against SARS-CoV-2. Sociodemographic information and medical history data was collected.

Results

Study findings indicate that as of October 2021, a seroprevalence rate of 75.9% (30% due to infection with Covid-19 virus and 45.9% due to vaccination), 95% CI (73.1-78.7). The results indicate that the prevalence of antibodies among those who unvaccinated and undiagnosed cases was 45.2% with 95% CI (39.9-50.5%).

The average age of participants was 37.6 years old. 49.2% were female and 50.8% were male. In relation to COVID-19, the following was found:

Conclusion

Our findings reveal a drastic rise in seroprevalence of SARS-CoV-2 antibodies both due to infection and due to vaccination. This information is useful for assessing the degree of herd immunity, and provides better understanding of the pandemic. Population-based seroprevalence studies should be conducted periodically to monitor the SARS-CoV-2 seroprevalence in Palestine and inform policymakers about the efficacy of the surveillance system and the public compliance with vaccination policies.

INTRODUCTION

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel virus that causes Coronavirus Disease 2019 (COVID-19) has infected over 460 million and caused the deaths of over six million people worldwide as of March 12, 2022 [1]. However, these figures underestimate the accurate cumulative prevalence or incidence of infection [2], due to accessibility of diagnostic testing, limited testing capacity [3], and asymptomatic infections [4].

Globally, seroprevalence studies using serologic testing have been recognized to provide better estimates of COVID-19 infection rates and prevalence on a population level in different populations, by capturing individuals with mild or no symptoms and others who never underwent diagnostic testing [5]. Assessing the cumulative prevalence is critical to understanding disease transmission rates and for understanding the evolution of the pandemic [5, 6]. The true prevalence of infection is believed to be 12.5 times more than the number of PCR-reported infections [7] as there are many asymptomatic infections, which constitute the majority of all SARS-COV-2 infections, yet are less likely to present for diagnostic testing [8, 9]. Consequently, the accuracy of such seroprevalence studies has been doubted due to insufficient specificity of the serologic assay for a low prevalence population and due to potential sampling bias [10].

In March 2020 a nationwide lockdown was implemented in Palestine, to contain the spread of COVID-19. As of March 2022, approximately 580,165 infections have been recorded, and 5,326 people have died in Palestine [11]. Previously, the authors of this study undertook a cross-sectional study [12] which revealed 0% seroprevalence of SARS-CoV-2 among a random sample of adults in the general population in the West Bank region of Palestine. Other studies [13] conducted among Palestinian adults in the West Bank yielded a seroprevalence of 36% and 40%, respectively (World Health Organization and Palestine Ministry of Health, 2022). There is a lack of data on the percentage of undiagnosed Palestinian population with previous mild or asymptomatic COVID-19. This repeated cross-sectional study was conducted to assess the seroprevalence of SARS-CoV-2 among a national sample of vaccinated and non-vaccinated adults in the West Bank region of Palestine, irrespective of the source of antibodies, be it due to infection with COVID-19 or due to vaccination or both. It is hoped the substantial seroprevalence of anti-SARS-CoV-2 antibodies in the Palestinian population should provide some measure of protection against future waves of COVID-19 in the country.

METHODS

Study design and participants

This repeated cross-sectional study was conducted between September 14, 2021 and October 21, 2021. The study included a random sample of adults aged 18 years and above, residing in 11 governorates in the West Bank, Palestine. The sample included 1451 individuals randomly selected from households using three-stage cluster sampling. The cluster of households or census tracts is considered to be a geographic location which is comprised of 124 households. The process for conducting cluster sampling included: (1) Selection of 125 census tracts (clusters) of households using the sampling frame provided by the Palestinian Central Bureau of Statistics

(PCBS), (2) Selection of 16 households randomly from each cluster and (3) selection of individuals at random from the list of individuals who are over the age of 18 and belong to the selected household. The clusters were selected using probability proportional to size (PPS) sampling, see [table 1]. The following steps were used to select the number of clusters within each population location: (1) the sampling interval (eg SI=N/m) which equals the total number of households divided by the total number of clusters need to be selected by the sample was calculated, (2) a random number R0 between 0 and SI was calculated, and (3) calculated Ri as R0+i*SI, a cluster is selected in Li if Ri belongs to the interval [Ci-1, Ci].

Data Collection

Sociodemographic information, risk factors, medical history, and COVID-19 related information (eg. Symptoms (due to infection or due to vaccination); vaccination status) were obtained during a face-to-face interview from 1451 participants (Table 2). Upon the interview, participants were asked if they would like to get tested for antibodies against COVID-19. Blood samples were collected from 911 participants. Blood samples were centrifuged, and serum was separated, labelled and stored at -20° C at AAUP laboratory until it was used.

Data collection was conducted by healthcare professionals at AAUP following standardized health protocols (World Health, 2020). Ethics approval for the research was obtained from the Helsinki committee ((PHRC/HC/737/20).) Participants recruited in the study gave written consent forms prior to participation in the study voluntary agreeing to participate in the research.

The study was conducted between September 14th 2021 and October 21st. Demographic and health Data was collected through face to face interviews with the 1451 participants [table 2]. Blood samples were drawn from 911 participants who agreed to participate in the sero study.

Sars-CoV-2 Antibody Testing

Serological tests for the 911 adequate serum samples were done using an Elecsys[®] Anti-SARS-CoV-2 assay by using the Cobas Analyzer cobas e 411 (Roche). The assay is an immunoassay that uses a recombinant protein representing the nucleocapsid (N) antigen. Serum samples in which the nucleocapsid (N) antigen was not detected were run using Elecsys Anti-SARS-CoV-2 S by using the Cobas Analyzer cobas e 411 (Roche). The assay detects antibodies to SARS CoV 2 spike protein RBD which are produced by mRNA vaccines. Samples from recovered and vaccinated cases with detected SARS-CoV-2 anti N and SARS-CoV-2 anti S antibodies were run as positive controls.

Statistical Analysis

Both univariate and bivariate inferential statistical methods were used for statistical analysis. Confidence interval using 95% confidence levels are used for estimation the seroprevalence across different segments within the Palestinian adult population living in the West Bank region. The lower and upper confidence limits of were calculated. Cross-tabulation method was used to explore bivariate relationships between seroprevalence and gender among other background variables. Chi-square test was utilized for testing if the statistical significance of bivariate relations among the different variables.

RESULTS

Sample Characteristics

In total, 1451 participants were enrolled in the study in which 911 undertook serological testing and blood sampling. Among these, 50.8% were males, 64.4% were married, 27.3% finished preparatory school, and 74.4% were non-refugees. The mean age of participants is 37.6. See table (2).

The main findings of the survey showed that a large majority of adult Palestinians (75.9%) developed antibodies against COVID-19. The results did not show significant difference (P-value=0.23) between males (74.2%) and females (77.5%) in the overall seroprevalence (Table 3). While there was a strong difference according to gender when we accounted for the source of antibodies whether it was due to infection or vaccination. The results showed that the prevalence of antibodies due to infection among females was twice (41.2%)

Unlike gender, , the study results showed quite a significant difference (P-value=0.000) in antibodies prevalence across age groups in the Palestinians society (figure 1). , the youngest age group (18-29 years) recorded the lowest prevalence of antibodies (69.2%), while the age group (30 -50 years) showed a prevalence of 77.9%. While the older group (50 years or older) got the highest prevalence of antibodies (84.1%) (figure 2). Such result could be attributed to the fact that the older population categories got more vaccinated than the younger population categories [Table 4].

An important factor that explained the variation in levels of antibodies prevalence is the vaccination and infection status among the Palestinian population. A new variable was computed based on the infection status with Covid-19 and the vaccination status. The new variable was used to segment the Palestinian population over the age of 18 into four categories described as follows: a) individuals who got infected and got vaccinated, b) individuals who got infected and did not get vaccinated, c) individuals who did not get infected and got vaccinated, d) individuals who did not get infected and did not get vaccinated.

The largest group of individuals within the Palestinian adult population living in the West Bank region are those who did not get infected and got vaccinated (46.4%) followed by the second largest group, which represents those who did not get vaccinated and reported (thought) that they did not get infected (40.0%) (figure 3)).

Our findings showed a strong bivariate relationship between antibody test results and infection-vaccination status (P-value=0.000) [table 5]. It is evident, the antibodies prevalence among those who did not get infected and got vaccinated is 94.0% in comparison to 45.2% among those who reported that they did not get vaccinated and did not get infected as well. Interestingly, 45.2% of those who did not get vaccinated and reported that they did not get infected with Covid-19 actually got infected without knowing, concluding this group of the population were asymptomatic to the infection.

DISCUSSION

The present large-scale study reports on the seroprevalence of anti-SARS-CoV-2 IgG antibodies between September 2021 and October 2021. To the best of our knowledge, this is the first seroepidemiological study describing the seroprevalence and the dynamics of antibodies after positive PCR-test or vaccination. There have not been many studies assessing seroprevalence after the beginning of vaccinations. Scroprevalence of COVID-19 one and half years after the start of the pandemic and several months after the vaccination rollout was 75.9%, varying among age groups, with the youngest age group having the highest seroprevalence. The high IgG \Box + \Box rate observed in our cohort was surely influenced by the high rate of vaccination within the Palestinian adults living in the West Bank region. However, this is the strength of the data provided herein. This finding was similar to a study conducted in Chile in which IgG positivity reached 77.4% five months after initiation of the vaccination [14]. There was no difference in gender for IgG positivity at the overall level, but there was a significant difference across gender in IgG positivity when we account for the source of positivity whether it's due to infection with Covid-19 or due to vaccination, see Table (6). This is result is consistent with other studies which found a statistical significance between IgG positivity and gender, [14],[15]. At the regional level, a three phased seroprevalence survey was conducted in Jordan, where results revealed that seroprevalence dramatically increased over time, with only a tiny fraction of seropositive individuals in August (0.3%), to increase up to more than 20-fold in October (7.0%)and to reach one-third of the overall population exposed by the end of 2020 (34.2%), [15]. Such results are compatible with similar seroprevalence survey conducted by the Palestinian ministry of health and WHO at the end of 2020. While similar results were obtained by a seroprevalence survey conducted by Arab American university in during June 2020. [12]. The most recent serology survey conducted by CDC over the period of September 2021 till December 2021 in the US, Seroprevalence increased from 36.5% (95% CI = 35.7-37.4) to 63.7% (95% CI = 62.5-64.8) among adults aged 18-49 years, 28.8% (95% CI = 27.9-29.8) to 49.8% (95% CI = 48.5-51.3) among those aged 50–64 years, and from 19.1% (95% CI = 18.4-19.8) to 33.2% (95% CI= 32.2–34.3) among those aged \geq 65 years. [16]. Approximately similar seroprevalence due to infection with Covid-19 (30%) was obtained by our serology survey that targeted adults over the age of 18 year during September 2021.

Two years after the start of the COVID-19 pandemic the actual prevalence of infection is still underestimated compared with PCR-confirmed COVID-19 cases. Older compared with younger individuals have lower antibody levels after vaccination. Approximately, 40% of the Palestinian adult population over the age of 18 years thought they were not infected and did not make the effort to get vaccinated. The study's findings showed 45% of those who thought they were not infected and did not get vaccinated, tested positive for SARS Covid-2 antibodies. By multiplying these two percentages, one can conclude that 18% of the Palestinian adult population who are over the age 18 got infected with SARS Covid-2 without knowing. This group of people could have contributed to a faster transmission rate in the spread of the virus, since they were

asymptomatic. Governments and public health officials should put more effort to detect asymptomatic cases through conducting seroprevalence surveys on a regular basis and develop regulations to encourage more people to get vaccinated. Tracking seroprevalence due to vaccination is an important issue, since vaccination contributes to the reduction of hospitalization among Covid-19 patients. A preliminary evidence has highlighted a possible association between severe COVID-19 and persistent <u>cognitive deficits</u>. [17]. Further research is required to confirm this association, determine whether cognitive deficits relate to clinical features from the acute phase or to mental health status at the point of assessment, and quantify rate of recovery. But this study comprises a good reason to encourage people to get vaccinated and health authorities to monitor the prevalence of vaccination and symptomatic cases on a regular basis.

Acknowledgements

The authors would like to thank PCBS staff who participated and managed data collection process. We would like to thank need to mention names to give them justice AAUP nursing school for the work they did on blood sample collection from participants. Finally, we would like to thank AAUP lab technicians we need to mention names and manager for their hard working on the blood samples analysis.

Contributors

Original Draft—Faisal Awartani. Writing Editing and Reviewing—Faisal Awartani, Nouar Qutub, Mohammed Asia, Waleed Theib. Lab Tests—Nouar Qutub. Data Analysis and Visualization--Faisal Awartani.

Funding

The authors have not declared any specific grant from any funding agency in the public, commercial or non-for-profit sector.

Competing Interests

None Declared.

Patient consent for publication

Not required.

REFERENCE

1 World Health Organization. WHO coronavirus (COVID-19) dashboard. Geneva: World Health Organization; 2021. https://covid19.who.int/table (accessed 12 Mar 2022).

2 Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review. Ann Intern Med. 2020;172(11):726-34.

3 Lieberman-Cribbin W, Tuminello S, Flores RM, et al. Disparities in COVID-19 Testing and Positivity in New York City. Am J Prev Med. 2020;59(3):326-32.

4 Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020;17(9):e1003346.

5 Busch MP, Stone M. Serosurveillance for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood Donor Populations. Clin Infect Dis. 2021;72(2):254-6.

6 Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020.

7 Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Intern Med. 2021;181(4):450-60.

8 Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study. J Infect. 2020;80(6):e1-e13.

9 McLaughlin CC, Doll MK, Morrison KT, et al. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results. medRxiv. 2020:2020.07.19.20157198.

10 Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. PLoS One. 2021;16(6):e0252617.

11 Worldometer. State of Palestine: Coronovirus cases. 2022. https://www.worldometers.info/coronavirus/country/state-of-palestine (accessed 17 Mar 2022).

12 Qutob N, Awartani F, Salah Z, et al. Seroprevalence of SARS-CoV-2 in Palestine: a cross-sectional seroepidemiological study. medRxiv. 2020:2020.08.28.20180083.

13 Maraqa B, Basha W, Khayyat R, et al. Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study. PLos One. 2021;16(10):e0258255.

14 Sauré D, O'Ryan M, Torres JP, et al. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. The Lancet Infectious Diseases. 2022;22(1):56-63

15 Bellizzi S, Alsawalha L, Sheikh Ali S, Sharkas G, Muthu N, Ghazo M, Hayajneh W, Profili MC, Obeidat NM. A three-phase population based sero-epidemiological study: Assessing the trend in prevalence of SARS-CoV-2 during COVID-19 pandemic in Jordan. One Health. 2021 Jul 10;13:100292. doi: 10.1016/j.onehlt.2021.100292. PMID: 34295958; PMCID: PMC8272624.

Clarke KE, Jones JM, Deng Y, et al. Seroprevalence of Infection-Induced SARS-CoV-2
Antibodies — United States, September 2021–February 2022. MMWR Morb Mortal Wkly Rep
2022;71:606-608. DOI: <u>http://dx.doi.org/10.15585/mmwr.mm7117e3</u>ext

17 Adam Hampshire, Doris A. Chatfield, Anne Manktelow MPhil, Amy Jolly, William Trender, Peter J. Hellyer, Martina Del Giovane, Virginia F.J. Newcombe, Joanne G. Outtrim, Ben Warne, Junaid Bhatti, Linda Pointon, Anne Elmer, Nyarie Sithole, John Bradley, Nathalie Kingston, Stephen J. Sawcer, Edward T. Bullmore, James B. Rowe, David K. Menon, Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort, eClinicalMedicine, Volume 47, 2022, 101417, ISSN 2589-5370,